Categories AlphaGraphs, Earnings, Other Industries

AngioDynamics posts in-line EPS of $0.25 in Q4

AngioDynamics (NASDAQ: ANGO) posted fourth-quarter earnings results on Wednesday before the regular trading hours. Net sales for the period increased 9% to $96.3 million, while adjusted net profit rose to $0.25 per share from $0.20 a year ago.

This came in line with the market expectation on earnings and above the revenue projection of $92.33 million.

angiodynamics Q4 2019 earnings

Most of the top line growth was driven by the international segment, where revenue grew 27%. In the US, net sales increased a modest 4.4%.

During the quarter, Oncology sales improved 26.5%, Vascular Interventions and Therapies unit sales grew 6.9% and Vascular Access net sales were up 4.9%

CEO Jim Clemmer said, “During the quarter, we strengthened our balance sheet and made significant progress towards our long-term portfolio management goals through the sale of our NAMIC Fluid Management business, setting us on a path towards becoming a leaner, more innovation-focused company.”

READ: Abbvie’s oncology push makes it an attractive stock

Outlook

AngioDynamics expects its fiscal year 2020 net sales to be in the range of $280 to $286 million and adjusted earnings per share in the range of $0.25 to $0.30. Additionally, the company expects gross margin to be in the range of 58% to 59%.

ANGO shares ended its last trading session up 0.69% on Tuesday. The stock has gained 3.5% in the year-to-date period.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top